$SNDX News

Syndax Pharmaceuticals Presents Data Showing Revuforj Achieved 90% Two-Year Overall Survival Post-Transplant In Acute Leukemia Patients, With Favorable Pharmacokinetic Profile Supporting Flexible Administration At ASCO 2026

Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including Ongoing Trials In Idiopathic Pulmonary Fibrosis, Newly Diagnosed Chronic Graft-Versus-Host Disease, And Newly Diagnosed Acute Leukemia

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

Syndax To Present Data Showing Favorable Post-Transplant Outcomes With Revumenib In Acute Leukemia And Highlight Ongoing Pivotal Trials At ASCO 2026

UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $37

Syndax Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?

Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $37

Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...

Syndax Pharmaceuticals Q1 Earnings Call Highlights

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Stock Slides After Q1 Revenue Misses Street Forecasts Despite 224% Growth

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals Q1 EPS $(0.48) Beats $(0.64) Estimate, Sales $64.864M Miss $70.439M Estimate

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Goldman Sachs Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $34

Mizuho Maintains Outperform on Syndax Pharmaceuticals, Lowers Price Target to $43

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template